363 related articles for article (PubMed ID: 18841419)
21. Venous thromboembolism in the medically ill patient: a call to action.
Bergmann JF; Kher A
Int J Clin Pract; 2005 May; 59(5):555-61. PubMed ID: 15857352
[TBL] [Abstract][Full Text] [Related]
22. The new oral anticoagulants, do they change the benefit vs. risk for thromboprophylaxis in association to ambulatory surgery?
Squizzato A; Romualdi E; Dentali F; Ageno W
Curr Opin Anaesthesiol; 2010 Dec; 23(6):722-5. PubMed ID: 20847691
[TBL] [Abstract][Full Text] [Related]
23. Low-molecular-weight heparin in oncology.
Zacharski LR; Loynes JT
Anticancer Res; 2003; 23(3C):2789-93. PubMed ID: 12926114
[TBL] [Abstract][Full Text] [Related]
24. [Prophylaxis and treatment of thromboembolism in oncology].
Kessler P
Vnitr Lek; 2009 Mar; 55(3):219-22. PubMed ID: 19378850
[TBL] [Abstract][Full Text] [Related]
25. Management of venous Thromboembolism in cancer: a brief review of risk-benefit approaches and guidelines' recommendations.
Djulbegovic B
J Support Oncol; 2010; 8(2):84-91. PubMed ID: 20464888
[TBL] [Abstract][Full Text] [Related]
26. Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice.
Soto-Cárdenas MJ; Pelayo-García G; Rodríguez-Camacho A; Segura-Fernández E; Mogollo-Galván A; Giron-Gonzalez JA
Palliat Med; 2008 Dec; 22(8):965-8. PubMed ID: 18952751
[TBL] [Abstract][Full Text] [Related]
27. Venous thromboembolism in cancer patients: expanding horizons.
Bergqvist D
Semin Thromb Hemost; 2002 Aug; 28 Suppl 3():19-23. PubMed ID: 12232819
[TBL] [Abstract][Full Text] [Related]
28. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
Fotopoulou C; duBois A; Karavas AN; Trappe R; Aminossadati B; Schmalfeldt B; Pfisterer J; Sehouli J;
J Clin Oncol; 2008 Jun; 26(16):2683-9. PubMed ID: 18509180
[TBL] [Abstract][Full Text] [Related]
29. Choosing the right heparin prophylaxis strategy in medical patients at risk for developing VTE: an evidence-based approach.
Harrington DW
Hosp Pract (1995); 2010 Nov; 38(4):18-28. PubMed ID: 21068523
[TBL] [Abstract][Full Text] [Related]
30. Lack of extended venous thromboembolism prophylaxis in high-risk patients undergoing major orthopaedic or major cancer surgery. Electronic Assessment of VTE Prophylaxis in High-Risk Surgical Patients at Discharge from Swiss Hospitals (ESSENTIAL).
Kalka C; Spirk D; Siebenrock KA; Metzger U; Tuor P; Sterzing D; Oehy K; Wondberg D; Mouhsine el Y; Gautier E; Kucher N
Thromb Haemost; 2009 Jul; 102(1):56-61. PubMed ID: 19572068
[TBL] [Abstract][Full Text] [Related]
31. Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care?
Burris HA
Semin Oncol; 2006 Apr; 33(2 Suppl 4):S3-16; quiz S41-2. PubMed ID: 16638456
[TBL] [Abstract][Full Text] [Related]
32. Targeting patients for anticoagulant prophylaxis trials in patients with cancer: who is at highest risk?
White RH; Chew H; Wun T
Thromb Res; 2007; 120 Suppl 2():S29-40. PubMed ID: 18023711
[TBL] [Abstract][Full Text] [Related]
33. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
Nishioka J; Goodin S
J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
[TBL] [Abstract][Full Text] [Related]
34. Risk of venous thromboembolism in patients undergoing cancer surgery and options for thromboprophylaxis.
Bergqvist D
J Surg Oncol; 2007 Feb; 95(2):167-74. PubMed ID: 17262765
[TBL] [Abstract][Full Text] [Related]
35. Venous thromboembolism: a review of risk and prevention in colorectal surgery patients.
Bergqvist D
Dis Colon Rectum; 2006 Oct; 49(10):1620-8. PubMed ID: 17019655
[TBL] [Abstract][Full Text] [Related]
36. A review of the practical advantages of low molecular weight heparin in the treatment of cancer-related venous thromboembolism.
Rhodes S; Bond S
Eur J Oncol Nurs; 2008 Dec; 12(5):425-9. PubMed ID: 18842458
[TBL] [Abstract][Full Text] [Related]
37. Does antithrombotic therapy improve survival in cancer patients?
Cunningham MS; Preston RJ; O'Donnell JS
Blood Rev; 2009 May; 23(3):129-35. PubMed ID: 19046797
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of prolonged thromboprophylaxis after cancer surgery.
Bradley CT; Brasel KJ; Miller JJ; Pappas SG
Ann Surg Oncol; 2010 Jan; 17(1):31-9. PubMed ID: 19707830
[TBL] [Abstract][Full Text] [Related]
39. Deep-vein thrombosis in malignancy: how long should patients be treated, and with what?
Merli GJ
Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S27-34. PubMed ID: 19530157
[TBL] [Abstract][Full Text] [Related]
40. Management of thromboembolism in hematologic malignancies.
Chong BH; Lee SH
Semin Thromb Hemost; 2007 Jun; 33(4):435-48. PubMed ID: 17525901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
